chlorambucil has been researched along with Erythremia in 49 studies
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 7.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "In studies to determine the optimal treatment for polycythemia vera, 431 previously untreated patients whose disease met established diagnostic criteria were entered into a prospective, randomized controlled trial between 1967 and 1974." | 6.65 | Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. ( Berk, PD; Donovan, PB; Ellis, JT; Goldberg, JD; Landaw, SA; Laszlo, J; Najean, Y; Pisciotta, AV; Silverstein, MN; Wasserman, LR; Weinfeld, A, 1981) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 3.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "A 73-year-old female developed pulmonary disease during treatment with chlorambucil for polycythemia vera." | 3.66 | Pulmonary disease with chlorambucil therapy. ( Cole, SR; Klatsky, AU; Myers, TJ, 1978) |
| "In studies to determine the optimal treatment for polycythemia vera, 431 previously untreated patients whose disease met established diagnostic criteria were entered into a prospective, randomized controlled trial between 1967 and 1974." | 2.65 | Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. ( Berk, PD; Donovan, PB; Ellis, JT; Goldberg, JD; Landaw, SA; Laszlo, J; Najean, Y; Pisciotta, AV; Silverstein, MN; Wasserman, LR; Weinfeld, A, 1981) |
| "Its use in the treatment of essential thrombocythemia began later in 1950." | 2.41 | Treatment of the myeloproliferative disorders with 32P. ( Berlin, NI, 2000) |
| "The excess risk of cancer after chlorambucil appears to persist for 5 years after stopping this treatment." | 1.29 | The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. ( Dresch, C; Najean, Y; Rain, JD, 1994) |
| "Simultaneous presentation of chronic lymphocytic leukemia and polycythemia vera is reported in a previously untreated patient." | 1.28 | Coexistent chronic lymphocytic leukemia and polycythemia vera requiring no treatment. ( Botelho de Sousa, A; Gouveia, J, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (79.59) | 18.7374 |
| 1990's | 7 (14.29) | 18.2507 |
| 2000's | 3 (6.12) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| WOODLIFF, HJ | 1 |
| Charbord, P | 1 |
| Neel, H | 1 |
| Caillou, B | 1 |
| Eydoux, P | 1 |
| Gardet, P | 1 |
| Parmentier, C | 1 |
| Freedman, ML | 1 |
| Berk, PD | 3 |
| Goldberg, JD | 3 |
| Silverstein, MN | 4 |
| Weinfeld, A | 2 |
| Donovan, PB | 3 |
| Ellis, JT | 3 |
| Landaw, SA | 3 |
| Laszlo, J | 3 |
| Najean, Y | 8 |
| Pisciotta, AV | 2 |
| Wasserman, LR | 7 |
| Brodsky, I | 1 |
| Morrison, JC | 1 |
| Dresch, C | 6 |
| Balcerzak, SP | 1 |
| Berlin, NI | 3 |
| McIntyre, OR | 1 |
| Tartaglia, AP | 1 |
| Tatarsky, I | 1 |
| Rain, JD | 4 |
| Nand, S | 1 |
| Stock, W | 1 |
| Godwin, J | 1 |
| Fisher, SG | 1 |
| Sánchez Fayos, J | 1 |
| Román Barbero, A | 1 |
| Nevado Reviriego, I | 1 |
| Tefferi, A | 1 |
| Pearson, TC | 1 |
| Messinezy, M | 1 |
| Lengfelder, E | 1 |
| Hehlmann, R | 1 |
| Hoffman, R | 1 |
| Queisser, W | 1 |
| Kalb, M | 1 |
| Cole, SR | 1 |
| Myers, TJ | 1 |
| Klatsky, AU | 1 |
| Westin, J | 1 |
| Maurice, P | 1 |
| Loeb, V | 1 |
| Newton, LK | 1 |
| Haq, AU | 1 |
| Botelho de Sousa, A | 1 |
| Gouveia, J | 1 |
| Conley, CL | 1 |
| Burger, T | 2 |
| Schmelczer, M | 2 |
| Molnár, L | 2 |
| Pajor, L | 2 |
| Koszorus, S | 2 |
| Meregalli, M | 1 |
| Fruchtman, SM | 1 |
| Peterson, P | 1 |
| Geller, SA | 1 |
| Rappaport, H | 1 |
| Hennemann, HH | 2 |
| Stecher, G | 2 |
| Libre, EP | 1 |
| Lewis, SM | 1 |
| Szur, L | 1 |
| Waldenström, JG | 1 |
| Delobel, J | 1 |
| Pecking, A | 1 |
| Kutti, J | 1 |
| Gilbert, HS | 2 |
| Krauss, S | 1 |
| Pasternack, B | 1 |
| Herbert, V | 1 |
| Binder, RA | 1 |
| Baxter, MF | 1 |
| Reinfrank, RF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial[NCT03003325] | Phase 2 | 127 participants (Actual) | Interventional | 2017-02-02 | Completed | ||
| Multicenter Phase 2 Study of Efficacy and Safety of Pegylated Interferon-alfa 2a in Polycythemia Vera Patients[NCT00241241] | Phase 2 | 40 participants | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for chlorambucil and Erythremia
| Article | Year |
|---|---|
Busulphan treatment of polycythaemia vera.
Topics: Busulfan; Chlorambucil; Clinical Trials as Topic; Humans; Leukemia; Polycythemia Vera | 1982 |
The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981.
Topics: Aged; Antineoplastic Agents, Alkylating; Chlorambucil; Follow-Up Studies; Humans; Middle Aged; Phleb | 1997 |
[Efficacious treatment of a fatal blood disease: polycythemia vera].
Topics: Acute Disease; Alkylating Agents; Busulfan; Chlorambucil; Humans; Hydroxyurea; Leukemia, Myeloid; Le | 1997 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
Treatment of the myeloproliferative disorders with 32P.
Topics: Adult; Aged; Alkylating Agents; Chlorambucil; Clinical Trials as Topic; Combined Modality Therapy; D | 2000 |
Idiopathic erythrocytosis, diagnosis and clinical management.
Topics: Aged; Arterial Occlusive Diseases; Bone Marrow; Chlorambucil; Diagnosis, Differential; Endocrine Sys | 2001 |
Natural history and management of polycythemia vera.
Topics: Acute Disease; Adult; Antineoplastic Agents; Bloodletting; Cell Transformation, Neoplastic; Chloramb | 1979 |
Treatment of polycythaemia vera.
Topics: Bloodletting; Busulfan; Chlorambucil; Cyclophosphamide; Humans; Injections, Intravenous; Internation | 1975 |
Neurologic complications of polycythemia and their impact on therapy.
Topics: Bloodletting; Chlorambucil; Clinical Protocols; Combined Modality Therapy; Humans; Nervous System Di | 1990 |
Current management of polycythemia vera and related diseases.
Topics: Allopurinol; Bloodletting; Chlorambucil; Erythropoiesis; Gout; Humans; Melphalan; Phosphorus Radiois | 1974 |
6 trials available for chlorambucil and Erythremia
| Article | Year |
|---|---|
Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.
Topics: Acute Disease; Chlorambucil; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Leu | 1981 |
Busulphan treatment of polycythaemia vera.
Topics: Busulfan; Chlorambucil; Clinical Trials as Topic; Humans; Leukemia; Polycythemia Vera | 1982 |
Maintenance therapy of 32P-induced remission in polycythemia vera. A clinical trial of chlorambucil and hydroxy-urea in 109 cases.
Topics: Chlorambucil; Drug Tolerance; Humans; Hydroxyurea; Long-Term Care; Phosphorus Radioisotopes; Polycyt | 1978 |
The choice of treatment in polycythaemia vera.
Topics: Bloodletting; Chlorambucil; Clinical Trials as Topic; Humans; Hydroxyurea; Phosphorus Radioisotopes; | 1986 |
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
Topics: Acute Disease; Age Factors; Bloodletting; Chlorambucil; Combined Modality Therapy; False Positive Re | 1986 |
Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies.
Topics: Acute Disease; Aged; Bloodletting; Bone Marrow; Bone Marrow Cells; Chlorambucil; Combined Modality T | 1986 |
34 other studies available for chlorambucil and Erythremia
| Article | Year |
|---|---|
IN-VITRO SENSITIVITY TESTS OF LEUKAEMIC CELLS TO CHEMOTHERAPEUTIC AGENTS.
Topics: Aminopterin; Animals; Antineoplastic Agents; Busulfan; Chlorambucil; Cyclophosphamide; Geriatrics; H | 1964 |
Redistribution of granulopoiesis from extramedullary territories to bone marrow in a case of spent polycythemia treated with alkylating agents.
Topics: Biopsy; Blood Cell Count; Bone Marrow; Busulfan; Chlorambucil; Female; Granulocytes; Humans; Karyoty | 1984 |
Common hematologic problems: diagnosis and treatment.
Topics: Aged; Anemia; Anemia, Macrocytic; Blood Cell Count; Blood Transfusion; Chlorambucil; Erythrocyte Ind | 1983 |
Polycythemia vera and alkylating agents.
Topics: Alkylating Agents; Chlorambucil; Humans; Leukemia; Polycythemia Vera | 1982 |
Myelosuppression in polycythemia vera: chemotherapy or radiotherapy?
Topics: Bone Marrow; Busulfan; Chlorambucil; Cyclophosphamide; Humans; Melphalan; Phosphorus Radioisotopes; | 1982 |
Influence of therapy on causes of death in polycythemia vera.
Topics: Chlorambucil; Hematocrit; Humans; Leukemia; Platelet Count; Polycythemia Vera; Risk; Thrombosis; Vei | 1981 |
The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group.
Topics: Aged; Bloodletting; Chlorambucil; Follow-Up Studies; Humans; Middle Aged; Neoplasms; Phosphorus Radi | 1994 |
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic; | 1996 |
[Treatment of polycythemia vera].
Topics: Antineoplastic Agents, Alkylating; Blood Component Removal; Chlorambucil; Erythrocyte Transfusion; H | 2001 |
[Secondary carcinoma: a complication of cytostatic therapy?].
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinogens; Chlorambucil; Female; Humans; Immunosuppressio | 1979 |
Myeloproliferative diseases.
Topics: Adult; Aged; Chlorambucil; Female; Humans; Male; Melphalan; Middle Aged; Myeloproliferative Disorder | 1977 |
Pulmonary disease with chlorambucil therapy.
Topics: Aged; Chlorambucil; Female; Humans; Polycythemia Vera; Pulmonary Alveoli; Pulmonary Fibrosis | 1978 |
Chromosome abnormalities after chlorambucil therapy of polycythaemia vera.
Topics: Aged; Bone Marrow; Bone Marrow Cells; Chlorambucil; Chromosome Aberrations; Chromosome Deletion; Fem | 1976 |
[The treatment of myeloproliferative syndromes].
Topics: Aged; Bloodletting; Busulfan; Chlorambucil; Female; Humans; Leukemia, Myeloid; Male; Myeloproliferat | 1975 |
The treatment of polycythemia vera.
Topics: Blood Transfusion; Bloodletting; Bone Marrow; Bone Marrow Cells; Chlorambucil; Chronic Disease; Eryt | 1976 |
Transformation of polycythemia vera to Ph-positive chronic myelogenous leukemia.
Topics: Bloodletting; Cell Transformation, Neoplastic; Chlorambucil; Humans; Leukemia, Myeloid, Acute; Leuko | 1990 |
Coexistent chronic lymphocytic leukemia and polycythemia vera requiring no treatment.
Topics: Aged; Aged, 80 and over; Bloodletting; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; | 1989 |
Polycythemia vera, diagnosis and treatment.
Topics: Aged; Blood Pressure; Bloodletting; Cerebrovascular Disorders; Chlorambucil; Diagnosis, Differential | 1987 |
Course and transformation of polycythaemia vera in relation to therapy.
Topics: Adult; Aged; Aged, 80 and over; Chlorambucil; Female; Humans; Leukemia; Leukemia, Radiation-Induced; | 1988 |
[Clinical course and transformation of polycythemia vera and its relation to applied therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Chlorambucil; Combined Modali | 1987 |
[A case of chronic lymphatic leukemia associated with polycythemia vera].
Topics: Aged; Chlorambucil; Humans; Leukemia, Lymphoid; Male; Polycythemia Vera; Prednisone | 1987 |
Acute leukemia in polycythemia vera.
Topics: Acute Disease; Antigens, Neoplasm; Bloodletting; Chlorambucil; Chromosome Aberrations; Chromosome Di | 1986 |
A cooperative study of polycythemia vera.
Topics: Aspirin; Chlorambucil; Dipyridamole; Humans; Leukemia; Polycythemia Vera; Prognosis | 1985 |
[The therapy of polycythemia vera].
Topics: Alkylating Agents; Anticoagulants; Bloodletting; Busulfan; Chlorambucil; Histamine H1 Antagonists; H | 1967 |
Polycythemia: a disease of all ages.
Topics: Adult; Aged; Alkaline Phosphatase; Blood Platelets; Blood Volume; Bone Marrow; Chlorambucil; Erythro | 1974 |
Blood and neoplastic diseases. Myeloproliferative disorders.
Topics: Adrenal Cortex Hormones; Androgens; Blood Transfusion; Bloodletting; Busulfan; Chlorambucil; Cycloph | 1974 |
From bad to worse? Treatment and leukemogenesis.
Topics: Antibiotics, Antineoplastic; Busulfan; Chlorambucil; Chromosome Aberrations; Chromosome Disorders; H | 1973 |
[Choice of treatment in polycythemia vera. 1. Efficacy of chemotherapy].
Topics: Chlorambucil; Humans; Hydroxyurea; Melphalan; Phosphorus Isotopes; Polycythemia Vera; Remission, Spo | 1973 |
Platelet production rate in polycythemia vera after myelosuppressive therapy.
Topics: Aged; Blood Cell Count; Blood Platelets; Busulfan; Cell Division; Cell Survival; Chlorambucil; Chrom | 1972 |
Pipobroman (Vercyte) - a new antineoplastic drug.
Topics: Anemia, Hemolytic; Antineoplastic Agents; Bone Marrow; Busulfan; Chlorambucil; Gastrointestinal Hemo | 1967 |
[Therapy of polycythemia vera].
Topics: Antimetabolites; Antineoplastic Agents; Bloodletting; Busulfan; Chlorambucil; Cyclophosphamide; Huma | 1969 |
Serum vitamin B12 content and unsaturated vitamin B12-binding capacity in myeloproliferative disease. Value in differential diagnosis and as indicators of disease activity.
Topics: Adult; Aged; Blood Proteins; Bloodletting; Chlorambucil; Chromatography; Cyclophosphamide; Diagnosis | 1969 |
Muramidase in polycythemia vera.
Topics: Alkaline Phosphatase; Busulfan; Chlorambucil; Cyclophosphamide; Humans; Leukocyte Count; Muramidase; | 1970 |
Electrophoretic patterns of human leukocyte alkaline phosphatase in polycythemia vera.
Topics: Alkaline Phosphatase; Busulfan; Chlorambucil; Electrophoresis; Gels; Humans; Leukocytes; Phosphorus | 1971 |